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doi:10.1016/j.jtcvs.2003.11.046TObjective: Certain patients with resectable lung cancer and severe respiratory
limitation due to emphysema may have a suitable operative risk by combining
cancer resection with lung volume reduction surgery. The purpose of this study is
to review our experience with such patients.
Methods: A review was conducted on 21 patients with lung cancer in the setting of
severe emphysema who underwent an operation designed to provide complete
cancer resection and volume reduction effect.
Results: In the 21 patients, the mean preoperative forced expiratory volume in 1
second was 0.7  0.2 L (29% predicted), residual volume was 5.5  1.0 L (271%),
and diffusing capacity for carbon monoxide was 8.0  2.2 mL/min/mm Hg (34%
predicted). In 9 patients, the cancer was located in a severely emphysematous lobe
and the lung volume reduction surgery component of the procedure was accom-
plished with lobectomy alone. In the remaining 12 patients, the cancer resection
lobectomy (n  9) and wedge resection (n  3) were supplemented with lung
volume reduction surgery. Final pathologic staging was stage I in 16 patients, stage
II in 2 patients, and stage III in 2 patients. One patient was found to have stage IV
disease due to multifocal tumors in separate lobes. There were no hospital deaths.
Postoperative complications included prolonged air leak in 11 patients, atrial fibril-
lation in 6 patients, and reintubation for ventilatory assistance in 2 patients. All
patients showed improved lung function postoperatively. Survival was 100% and
62.7% at 1 and 5 years, respectively.
Conclusions: Patients with severe emphysema and resectable lung cancer who have
a favorable anatomy for lung volume reduction surgery may undergo a combined
cancer resection and lung volume reduction surgery with an acceptable risk and
good long-term survival.
Early-stage non–small cell lung cancer is best treated by completeanatomic resection. Patients with resectable lung cancer but withassociated advanced emphysema are often precluded from surgerydue to severe respiratory limitation. For these patients alternativetreatment strategies including radiation therapy, with or withoutchemotherapy, yield comparatively poor results.1,2 Furthermore, ra-
diation therapy may lead to the same degree of reduction in pulmonary function as
he Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 5 1323
General Thoracic Surgery Choong et al
G
TSsurgical resection. Thus, patients with severely limited pul-
monary function represent as much a management problem
for the radiation oncologist as for the surgeon.3 This di-
lemma is further compounded for surgeons by the lack of a
precisely definable point at which the risk-to-benefit ratio
for resection becomes unfavorable, particularly in light of
improvements in the anesthetic, surgical, and postoperative
treatment of patients with advanced emphysema.
We previously reported the beneficial early- and inter-
mediate-term results of lung volume reduction surgery
(LVRS) in 150 selected patients with advanced emphyse-
ma.4,5 The long-term outcome of bilateral LVRS in 250
consecutive emphysema patients showed that LVRS pro-
duces significant functional improvement.6 The benefit ap-
pears to last at least 5 years for the majority of these
patients.
Certain highly selected patients with clinically resectable
lung cancer and severe respiratory limitation due to emphy-
sema may have an acceptable operative risk by combining a
suitable cancer resection with LVRS. This combination
would provide the best treatment for early-stage lung cancer
while at the same time be a palliative treatment for the
symptoms of emphysema. We previously reported our early
results in 5 patients who underwent a combined lung cancer
resection and LVRS.7 The purpose of this report is to
describe our experience in a larger number of patients with
a longer follow-up who had combined cancer resection with
LVRS at our institution.
Methods
Patient Population
Between January 1993 and December 2001, over 1000 patients
with severe emphysema were evaluated at Barnes Hospital as
potential candidates for LVRS. Among these, 332 were deter-
mined to be acceptable candidates and went on to have 280
bilateral and 52 unilateral LVRS procedures. Among the patients
who were referred for evaluation and accepted for LVRS opera-
tions were 5 patients (1.5%) in whom chest x-ray films showed a
pulmonary nodule suspicious for carcinoma. Another 16 patients
were referred primarily for evaluation of newly diagnosed or
suspected lung cancer in the setting of severe emphysema. These
21 patients form the basis for this report. A review was conducted
from the medical records and prospective database that contains
serial pulmonary function studies and exercise testing on all pa-
tients pre- and post-LVRS. The mean follow-up was 3.9 years with
a minimum time interval since surgery of 1 year. Follow-up was
complete and based on routine appointments after surgery as well
as direct patient or family contact. This study was reviewed and
approved by the Washington University School of Medicine Hu-
man Studies Committee. This report does not include patients who
were found to have incidental cancer in the resected pathologic
specimens following LVRS.
The patient evaluation included physical examination, pulmo-
nary function tests with lung volumes determined by plethysmog-
raphy, arterial blood gas analysis (at rest on room air), chest
1324 The Journal of Thoracic and Cardiovascular Surgery ● Maradiograph, standardized computed tomography (CT) of the chest
including views of the liver and adrenal glands, radionuclide
ventilation-perfusion lung scan, 6-minute walk test, and Medical
Research Council dyspnea scale. Systemic spread of disease was
evaluated by brain CT and radionuclide bone scan.
Details of the selection process for lung volume reduction were
reported previously.4-6 Marked hyperinflation of the chest and
adequate regional distinction in the destruction pattern of emphy-
sema to provide “target areas” of useless lung accessible to surgi-
cal resection were critical selection criteria in all patients.
The majority of patients judged suitable for surgery were
enrolled in a preoperative pulmonary rehabilitation and smoking
cessation program lasting 6 to 8 weeks. Patients were then reas-
sessed the week before surgery by an interval history and physical
examination, chest radiograph, chest CT, complete pulmonary
function tests, arterial blood gas, 6-minute walk test, and dyspnea
questionnaire. The postrehabilitation, immediate preoperative data
were used as the baseline for comparisons with postoperative data.
Five patients were felt to be in suitable physical condition when
initially evaluated and went directly to surgery without pulmonary
rehabilitation. In these patients, their initial evaluation measure-
ments were used as the baseline for comparison.
Flexible bronchoscopy was performed on all patients. Biopsy
of an endoscopically visible tumor or fine needle aspiration of a
peripheral pulmonary lesion was performed when feasible. Medi-
astinoscopy was performed for all patients with proven lung cancer
and for those with a suspected lung cancer when the suspicious
lesion was larger than 1 cm, centrally located, or associated with
lymph node enlargement on CT images. The general treatment
policy of our group is that patients with histologically proven N2
disease are not offered surgery due to the poor 5-year survival in
this group of patients. The purpose of performing a cervical
mediastinoscopy in this subset of patients is to exclude N2 disease
before proceeding to a combined lung cancer resection and LVRS
as the primary justification for the procedure in these patients was
to resect the cancer, employing our usual criteria and staging
procedures.
Surgical Technique
Bilateral procedures were performed through a median sternotomy
in 10 patients. The remaining 11 patients had a muscle-sparing
thoracotomy for a unilateral procedure. One patient had a previous
bleb excision and pleurectomy on the left side due to recurrent
spontaneous pneumothorax and required staged thoracotomies for
a right upper lobe volume reduction and subsequent completion
left upper lobectomy for cancer. The decision to perform either a
wedge resection or a lobectomy depends upon the location of the
tumor and the distribution and severity of emphysema. Lobectomy
is generally not performed in patients with severe emphysema
unless there is a heterogenous distribution of emphysema and the
tumor is located within a destroyed, virtually functionless lobe. If
the tumor is in the middle lobe and there are suitable target areas
for LVRS in other lobes, then a middle lobectomy may be per-
formed in conjunction with ipsilateral or bilateral LVRS. If the
tumor is located in the best-preserved lobe other than the middle
lobe, then either a wedge resection is performed or the patient is
considered not to be a suitable candidate. An ipsilateral or a
contralateral LVRS is added to the cancer resection if there is a
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expected to result in a likely improvement in the patient’s postop-
erative pulmonary function. Pleural tents were created in 7 patients
for residual space remaining at the apex of the chest at the end of
the procedure.
Immediate extubation in the operating room or shortly there-
after in the postanesthesia recovery area was achieved in all
patients. One patient who was hemodynamically unstable required
immediate reintubation, with successful extubation 2 days later.
Postoperative Management
A thoracic step-down unit provided specialized postoperative nurs-
ing care. A thoracic epidural catheter for continuous analgesia was
placed with fluoroscopic guidance immediately prior to the thora-
cotomy as per our standard postoperative pain protocol. This
decreased the need for systemic narcotics and provided optimal
pain management with minimal risk for respiratory depression.
Chest physiotherapy and ambulation, initiated on the first post-
operative day by experienced physical therapists and thoracic
surgical nurses, was continued throughout the hospital stay. Post-
operative bedside bronchoscopy and mini-tracheostomy placement
were used when necessary to clear thick secretions.
Statistical Analysis
Descriptive statistics are expressed as mean  standard deviation
unless otherwise specified. Categorical data are expressed as
TABLE 1. Pulmonary function and exercise test results be
Pre–pulmonary
rehabilitation Preoperative
6 m
posto
n 16 21
FEV1, L (% predicted) 0.7 0.2 (27%)* 0.7 0.2 (29%) 1.0
RV, L (% predicted) 5.3 0.4 (260%)* 5.5 1.0 (271%) 3.2
DLCO, mL/min/mm Hg
(% predicted)
8.4 2.8 (35%)* 8.0 2.2 (34%) 8.9
Six-minute walk
(feet)
854 332† 906 354 1240
MRC 3.4 0.7* 3.5 0.8 0.7
FEV1, Forced expiratory volume in 1 second; RV, residual volume; DLCO, dif
scale.
*P  .05 for paired analyses with preoperative scores.
†P  .05 for paired analyses with preoperative scores.
‡P  .001 for paired analyses with preoperative scores.
TABLE 2. Alveolar gas exchange and oxygen supplementa
Preoperative
n 21
PACO2 (mm Hg) 42 4
PAO2 (mm Hg) 67 10
Steroid use (%) 19
Supplemental oxygen
Required continuously (% of patients) 57
Required during exercise (% of patients) 86counts and proportions. Comparisons were done with paired,
The Journal of Thoracic2-tailed t test for means of normally distributed continuous vari-
ables and the Wilcoxon rank sum test for skewed data. Chi-square
or Fisher exact test was used to analyze differences among the
categorical data. Kaplan-Meier estimate was used to depict sur-
vival. All data analysis was performed using SPSS (SPSS 11.0 for
Windows: SPSS Inc, Chicago, Ill).
Results
Baseline
The mean age of the 21 patients was 66  7 years (median:
65.5 years, range: 53-78 years). Eight were men and all
were former smokers. All patients, with the exception of
one who complained of chest wall pain, had no symptoms
from their cancer with the suspicious lesion being first
found on routine chest radiograph. All had symptoms of
advanced emphysema. Twelve (57%) suffered from dys-
pnea at rest and required continuous supplemental oxygen,
and 18 (86%) required oxygen supplementation during ex-
ercise. Seven (33%) patients were taking prednisone when
first evaluated, three of whom were completely weaned
prior to surgery. Preoperative pulmonary function, exercise
test results, alveolar gas exchange, and oxygen supplemen-
tation are depicted in Tables 1 and 2.
During the baseline evaluation process, two patients
and after surgery
s
tive
1 year
postoperative
3 years
postoperative
5 years
postoperative
20 14 7
0%)‡ 1.1 0.4 (43%)‡ 0.9 0.2 (34%)† 0.8 0.2 (28%)*
52%)‡ 3.4 0.6 (161%)‡; 3.6 0.7 (163%)‡ 4.1 1.2 (195%)†
6%)* 9.0 3.6 (36%)* 8.9 3.2 (35%)* 8.4 1.2 (30%)*
1292 171† 1171 113† 1101 126*
0.8 0.8‡ 1.1 0.4‡ 1.6 0.5‡
capacity for carbon monoxide; MRC, Medical Research Council dyspnea
requirements before and after surgery
months
operative
1 year
postoperative
3 years
postoperative
5 years
postoperative
21 20 14 7
9 5 39 4 44 6 44 6
3 11 73 11 69 9 68 9
9 6 7 14
4 6 18 20
38 47 55 80fore
onth
pera
21
0.3 (4
0.9 (1
2.9 (3
171†
0.6‡
fusingtion
6
post
3
7were found to have extensive coronary artery disease. One
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undergoing pulmonary resection and the other underwent
coronary bypass grafting of 3 vessels 3 months prior to
undergoing pulmonary resection. Two other patients were
found to have cardiomyopathy and reduced left ventricular
ejection fraction (20%) resulting from a prior myocardial
infarction.
All patients were felt to have early-stage, resectable lung
cancer. Six patients had biopsy-proven malignancy prior to
surgery. No evidence of systemic spread of disease was
evident following the various staging procedures. In all
patients the lesion was in a location suitable for a wedge
resection or lobectomy.
Surgical Procedure and Pathology
Fifteen of the 21 patients had mediastinoscopy, which in all
cases proved negative for regional lymph node involve-
ment. In 9 patients, the cancer was located in a severely
emphysematous lobe and the volume reduction component
of the procedure was accomplished by an anatomic lobec-
tomy alone. In the remaining 12 patients, the cancer resec-
tion (lobectomy: n  9; wedge resection: n  3) was
supplemented with additional LVRS. The additional resec-
tion was ipsilateral in 3 patients, contralateral in 5 patients,
and bilateral in 4 patients. Final pathologic staging was
stage I in 16 patients, stage II in 2 patients, and stage III in
2 patients due to 2 separate tumor nodules within the same
lobe (T4 disease). Cervical mediastinoscopy was performed
TABLE 3. Location of the tumor, operative procedure pe
patients
Patient Location of tumor Procedu
1 Right upper lobe Lobectomy and con
2 Right lower lobe Lobectomy and con
3 Right middle lobe Lobectomy and con
4 Left upper lobe Wedge and contrala
5 Right middle lobe Lobectomy and ipsil
6 Right lower lobe Wedge and ipsilater
7 Left upper lobe Lobectomy only
8 Left upper lobe Lobectomy and con
9 Right lower lobe Wedge and contrala
10 Left lower lobe Lobectomy only
11 Left upper lobe Lobectomy only
12 Right lower lobe Lobectomy only
13 Right upper lobe Lobectomy and con
14 Right upper lobe Lobectomy and ipsil
15 Right upper lobe Lobectomy only
16 Left upper lobe Lobectomy only
17 Left upper lobe Lobectomy only
18 Left upper lobe Lobectomy only
19 Right upper lobe Lobectomy and con
20 Right upper lobe Lobectomy only
21 Left upper lobe Lobectomy and con
LVRS, Lung volume reduction surgery; NSCLC, non–small cell lung carcinin both patients with stage III disease (T4 N1 M0, T4 N0
1326 The Journal of Thoracic and Cardiovascular Surgery ● MaM0) and did not reveal any evidence of mediastinal meta-
static disease. One patient was found to have stage IV
disease due to 2 multifocal tumors located in separate lobes
(TX N0 M1 disease). The operative procedure as well as the
location, histology, and pathologic stage of the resected
tumor for each patient are depicted in Table 3.
Hospital Course
There was no hospital mortality. The most common post-
operative complication was prolonged air leak (7 days) in
11 patients (52%). Four of these patients were discharged
with a chest tube connected to a Heimlich valve until
complete resolution of air leak. Atrial fibrillation was noted
in 6 patients (29%) and reintubation for ventilatory assis-
tance in 2 patients (9%). One patient was taken back to the
operating room for reexploration because of bleeding. A
mini-tracheostomy was placed in 7 patients (33%) either in
the operating room or later at the bedside. All patients were
weaned from mechanical ventilation prior to discharge. The
median length of hospitalization was 9 days (range: 5-24
days).
Follow-up Information
No patient was lost to follow-up. Nine patients (43%) had
late death. The cause of death was recurrent cancer in 4
patients, respiratory failure in 3 patients, and cardiac failure
in 2 patients. Kaplan-Meier estimation of survival at 1, 3,
and 5 years was 100%, 73.7%, and 62.7%, respectively
ed, pathologic features including stage for each of the
Histology Stage
eral LVRS Adenocarcinoma I
eral LVRS Adenocarcinoma I
eral LVRS Adenocarcinoma I
l LVRS Adenocarcinoma IIIb
l LVRS Adenocarcinoma I
RS Squamous I
Adenocarcinoma I
eral LVRS Squamous IIb
l LVRS Squamous IV
Squamous I
Poorly differentiated NSCLC I
Squamous I
eral LVRS Poorly differentiated NSCLC I
l LVRS Adenocarcinoma I
Adenocarcinoma I
Adenocarcinoma IIa
Adenocarcinoma I
Adenocarcinoma I
eral LVRS Squamous I
Squamous I
eral LVRS Squamous IIIbrform
re
tralat
tralat
tralat
tera
atera
al LV
tralat
tera
tralat
atera
tralat
tralat
oma.(Figure 1). Kaplan-Meier estimation of survival of patients
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and 68.0%, respectively.
Cancer Status
Two patients received adjuvant radiation therapy as a result
of unsuspected positive parenchymal margin identified in 1
patient by formalin fixed histology and by a positive hilar
lymph node in the other patient. At the time of follow-up, 5
patients (24%) developed recurrent disease, first noted at 7,
8, 35, 46, and 48 months after resection. Four of the 5
recurrences were first noted on routine follow-up chest
radiograph. The remaining patient complained of blood-
streaked sputum, prompting further investigation. Further
tests, such as chest and brain CT and radionuclide bone
scan, F-18 fluorodeoxyglucose positron emission tomogra-
phy (PET) scan, and biopsy, were all performed to confirm
local and systemic recurrence of disease. All 5 patients went
on to receive treatment under the care of a medical oncol-
ogist. Four subsequently died due to metastatic disease and
1 patient remains alive with evidence of disease. Kaplan-
Meier estimation of freedom from cancer recurrence at 1, 3,
and 5 years was 90.5%, 84.0%, and 68.7%, respectively
(Figure 2). Kaplan-Meier estimation of freedom from can-
cer recurrence in patients with stage I disease at 1, 3, and 5
years was 90.0%, 84.0%, and 69.3%, respectively.
Functional Results
Pulmonary function tests are shown in Table 1. Spirometry,
lung volumes, and gas exchange improved after surgery.
The forced expiratory volume in 1 second (FEV1) and
residual volume (RV) showed a statistically significant im-
provement between preoperative values and each time point
of follow-up through 3 years. Although the FEV1 returned
to baseline by 5 years, the RV remained significantly im-
proved. As with LVRS patients in general, there was no
Figure 1. Kaplan-Meier estimation of survival at 1, 3, and 5 years.statistical significance between the initial evaluation and
The Journal of Thoracicpostrehabilitation FEV1 and RV measurements. The diffus-
ing capacity for carbon monoxide remained unchanged
throughout all time points.
Supplemental oxygen requirements at rest substantially
declined after surgery (57% preoperatively vs 6%, 18%, and
20% at 1, 3, and 5 years after surgery, respectively). Pre-
operatively 86% of patients required supplemental oxygen
with exertion. At 1, 3, and 5 years the requirement was 47%,
55%, and 80%, respectively, as shown in Table 2.
Functional improvement was also measured by the
6-minute walk test and results are shown in Table 1. Sig-
nificant improvement in preoperative physical stamina re-
sulted in those patients who underwent pulmonary reha-
bilitation. Further improvement in performance was
evident after surgery. This improvement was maintained
throughout follow-up with a gradual decline toward base-
line at 5 years.
As depicted in both Table 1 and Figure 3, 89% of
patients reported improvement in symptoms of dyspnea at 6
months following surgery. At 1 year 88% remained im-
proved, 8% were unchanged, and 4% showed worsening.
These improvements were sustained throughout follow-up,
with only 17% of patients measured reporting a worse score
at 5 years.
Discussion
Cigarette smoking is an important cause of both lung cancer
and emphysema.8,9 Complete resection by lobectomy or
pneumonectomy remains the best treatment for patients
with early-stage lung cancer. The presence of severe em-
physema in patients with early-stage lung cancer can pre-
clude them from anatomic resection. We previously re-
ported on a small series of patients, otherwise considered
inoperable on the basis of overall lung function and oxygen
dependency, in whom a combination of LVRS and cancer
7
Figure 2. Kaplan-Meier estimation of freedom from recurrence of
disease at 1, 3, and 5 years.resection proved worthwhile. There are a number of studies
and Cardiovascular Surgery ● Volume 127, Number 5 1327
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tigations and postoperative results to predict preoperative
risk factors. In one study, FEV1 was found to be the best
predictor of postoperative mortality.10 Other studies found
that the minimum criteria for a lobectomy were maximal
voluntary ventilation greater than 40% of predicted value,
an FEV1 value greater than 1 L, and an FEV25-75 value
greater than 0.6 L.11,12 In another study, diffusing capacity
was found to be the most important predictor of death and
pulmonary complications.13 The authors recommended that
patients with a corrected diffusing capacity of less than 60%
of predicted value should not be considered for major pul-
monary resection. Other investigators attempted to better
define the operative risks in patients with marginal pulmo-
nary reserve by quantifying differential lung function by
using xenon 133 ventilation radiospirometry with or without
technetium 99 perfusion scanning.14-17 One study found that
patients with a predicted postresection FEV1 value of less
than 1 L were considered unfit for surgery.17 Impaired
maximal oxygen consumption or the loss of pulmonary
vascular compliance during exercise was suggested in other
studies to help define patients at high risk for resection.
Recent studies reported on other methods to determine
suitability for pulmonary resection in patients with moder-
ate to severe respiratory limitation.18-20 Korst and col-
leagues18 noted an improvement or minimal loss of pulmo-
nary function following lobectomy for the treatment of
non–small-cell lung carcinoma in 13 patients with an FEV1
of less than or equal 60% of predicted value and an FEV1/
forced vital capacity ratio of less than or equal 0.6. A
scoring system combining these 2 parameters helped to
identify patients who may have only a limited reduction or
even an improvement of pulmonary function following lo-
bectomy. Carretta and associates19 reported a subgroup of
Figure 3. Modified Medical Research Council dys10 patients in whom a higher radiological visual assessment
1328 The Journal of Thoracic and Cardiovascular Surgery ● Maof emphysema correlated to an unchanged or even an in-
crease of pulmonary function following a lobectomy. The
radiological visual assessment utilized a scoring system that
is a sum of the grading score of emphysema seen on lateral
chest radiograph and chest CT scan. Edwards and cowork-
ers20 extended the selection criteria for lobectomy in pa-
tients with a predicted postoperative FEV1 of less than 40%
if the tumor was resectable, the target lobe was both em-
physematous and contributed to less than 10% of overall
perfusion, and there was evidence of hyperinflation on ra-
diological assessment. Despite these various findings, no
single test has been found to best define the patients who
will and will not tolerate resection. Instead, these investi-
gations, together with the physical condition of the patient
and the surgeon’s experience, help to select patients suitable
for surgical resection.
Lung volume reduction surgery in well-selected patients
with severe emphysema results in postoperative improve-
ment of symptoms and measured pulmonary function.5 The
combination of lung cancer resection with LVRS offers
selected patients who have concomitant early lung cancer
and severe emphysema the opportunity to undergo resection
of their cancer with improvement rather than further reduc-
tion in their pulmonary function. By traditional criteria
these patients would otherwise be considered unsuitable
surgical candidates because of the limited pulmonary func-
tion. In this series, all patients had pulmonary function
values in one or more categories well below the traditionally
accepted minimal criteria for lobectomy. Following the
combined surgery, these patients reported early- and long-
term benefits similar to those who had LVRS alone.6 These
early improvements were followed by a slow gradual de-
cline of the pulmonary function tests, similar to the patients
who had LVRS alone.6 The Kaplan-Meier estimation of
scale respondent’s score change after surgery.pneasurvival at 1, 3, and 5 years in this group of patients was
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compares well to the reported long-term outcome of bilat-
eral lung volume reduction in 250 consecutive patients with
emphysema where the Kaplan-Meier estimation of survival
at 1, 3, and 5 years was 93.6%, 84.4%, and 67.7%, respec-
tively.6
Lobectomy is generally not performed in patients with
severe emphysema unless there is a heterogenous distribu-
tion of emphysema and the tumor is located within a de-
stroyed, virtually functionless lobe. In our series, 9 patients
had their cancer within a severely emphysematous lobe and
complete lobectomy served to achieve the dual function of
cancer resection and LVRS. Other patients, however, had
their cancer located in a lobe separate to other additional
LVRS target areas. In this group of patients, a small periph-
eral cancer was removed either by a wedge resection or
segmentectomy; a centrally located cancer was removed by
a lobectomy. These patients had supplementary LVRS in
addition to their cancer resections. If the tumor was in the
middle lobe and there were suitable target areas for LVRS
in other lobes, then a middle lobectomy was performed in
conjunction with ipsilateral or bilateral LVRS. If the tumor
was located in the best-preserved lobe other than the middle
lobe, then either a wedge resection was performed or the
patient was not considered to be a suitable candidate.
There are several limitations to this study. It is small
series of highly selected patients. It would not be appropri-
ate to generalize the application of combined lung cancer
resection and LVRS for all patients with resectable lung
cancer associated with severe emphysema. Limited resec-
tion by wedge or segmentectomy may also lead to an
increased risk of local or earlier recurrence; however, it is
still likely the best option for a curative result. Primary
radiation treatment is an alternative therapy for these pa-
tients with limited pulmonary reserve. However, radiation
pneumonitis and fibrosis will worsen pulmonary function
without providing any lung volume reduction effect. The
rate of cure with radiation therapy is also inferior to that
accomplished by surgical resection. A combined resection
in suitable patients is therefore the only strategy that can
potentially provide both a curative procedure and improve-
ment in pulmonary function.
In summary, combined cancer resection and LVRS al-
lows selected patients with early lung cancer and advanced
emphysema to undergo the optimal treatment modality of
cancer resection at a low risk with improvement of their
pulmonary status.
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Discussion
Dr Larry R. Kaiser (Philadelphia, Pa). Among the added benefits
of lung volume reduction surgery has been the realization that
patients with much more severe obstructive lung disease poten-
tially are candidates for pulmonary resection. It is almost a fact that
very few patients are not candidates for resection on the basis of
pulmonary function alone. This recognition has benefited many
more patients than just the group undergoing lung volume reduc-
tion.
So I have several questions. Cliff, the group had a fairly high
incidence of air leaks (52%) despite the use of buttressing. Is there
any explanation for that? And did the air leaks occur from the area
of the cancer resection, from the area where you did the lung
volume reduction, or from both areas?
Dr Choong. I believe the majority of the air leaks would have
occurred from the area of the lung volume reduction surgery. The
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terms of the frequency of air leakage, would not have been any
different than other cases of lobectomy for patients without severe
emphysema.
In terms of the high incidence of air leak of 52%, this is not
very much different than the reported series by Anna Maria Cic-
cone last year where she reported 250 patients who had consecu-
tive bilateral lung volume reduction surgery and the air leakage
was about 50%. And also in other series, for example, Dr Rob
McKenna, who reported his series of 325 lung volume reduction
surgeries in the journal of Chest in 1996, the air leakage was just
slightly below 50%. So I think the incidence of 52% itself, al-
though high, is fairly expected in patients who undergo lung
volume reduction surgery.
Dr Kaiser. But you defined it as prolonged air leak, so I
assume that’s greater than 7 days, so that does seem a little bit
high. But you’re absolutely right. Do you have comments on that?
Dr Cooper. No, except it is the same. Maybe we should do
better. These people don’t come out of the operating room with air
leaks, but within hours or by the next day they frequently have
them. And on the occasion when we have had to explore patients,
we have usually found that it is either in the fissures or often a
remote area, not the staple line, because once you’ve done volume
reduction, the distending force on the remaining pleura is quite
extensive and just a little cough or strain can tear it.
Dr Kaiser. How do you decide who is a candidate for this
approach? I mean who is to say you couldn’t take some of these
patients and just do a resection? It seems to me that those patients
who have a lower lobe lesion and upper lobe–predominant em-
physema, without going into details, it seems that upper lobe–
predominant emphysema does tend to be associated with a better
functional outcome in these patients. So how do you decide who is
a candidate for this procedure as opposed to just doing the resec-
tion alone? And who won’t you operate on, for that matter? Who
do you turn down?
Dr Choong. I think it is important to realize that this is a very
highly selected group of patients, and the criteria that we have set
for these patients are, first, they must have clinical evidence of
early lung cancer. If they have any evidence of N2 disease or
metastatic disease, they are excluded from this operation. Second,
they need to have suitable target areas, similar to those patients
selected for LVRS, heterogeneous, severe emphysema, suitable
target areas. We were fortunate to have treated patients where the
cancer was also located in a severely emphysematous lobe,
thereby, when we did the lobectomy itself, for example, in 9
patients, the lobectomy itself served both the function of LVRS
and cancer resection. So personally I think it is important to realize
that this is a group of patients who are highly selected, who are
treated by very experienced surgeons, and together with the expe-
rience and those criteria, I would think those would be the prereq-
uisites.
Dr Kaiser. How much lung tissue do you take for your lung
volume reduction? Is it the same amount that you take for your
isolated lung volume reduction procedures or do you take a little
bit less? Because you are, in some of these cases, resecting
otherwise functioning parenchyma and then going ahead and doing
a volume reduction procedure because that is the targeted area. So
1330 The Journal of Thoracic and Cardiovascular Surgery ● Mahow much do you take? I know just the right amount is the right
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Dr Choong. I would think that the group would still be taking
about 20% to 30% of the lung when they are planning to do just a
volume reduction of the upper lobe. However, patients are having
lobectomy as their lung volume reduction surgery and cancer
surgery resection, then, as you can see, some of those patients do
not require any additional lung volume reduction.
Dr Cooper. I think it’s fair to say that no lobectomies were
done if the cancer was in the better preserved part of the lung.
There may have been a couple wedges in that situation and the rest
were lobectomies. I think there could be no lobectomy done if the
cancer was localized in the better part rather than the worst part of
the lung in a patient with heterogeneous pattern of emphysema.
Dr Kaiser. That’s the question.
Dr Cooper. They would not be candidates, I think.
Dr Thomas W. Rice (Cleveland, Ohio). Congratulations on an
excellent presentation, Clifford. Do you know about the denomi-
nator of this study, about patients who had emphysema and lung
cancers who did not have surgery? Why didn’t they? What was
their outcome?
Dr Choong. I do not know the number of patients who were
referred with cancer and emphysema and were turned down for
surgery. I do not have those data with me.
Dr Mark J. Krasna (Baltimore, Md). Dr Choong, how many
of these patients had PET scans as part of their evaluation?
Knowing what we’ve heard about the chances of finding occult
micrometastases in lymph nodes and the fact that these patients are
high risk, would your group either advocate routine PET scanning
in all these patients or would you actually do mediastinoscopies on
them first even if they had a negative CT scan?
Dr Choong. The patients now routinely undergo PET scanning
if they have either a proven lung cancer or are highly suspicious
for lung cancer. Early in the series not all the patients had a PET
scan because the technology of PET scan was still evolving. So the
answer would be yes; first, PET scan would be performed now.
Second, in terms of cervical mediastinoscopy, that would be per-
formed if the patient had proven lung cancer or if the location of
the tumor was central or there was CT evidence or PET scan
evidence of mediastinal lymph node disease involvement.
Dr Kaiser. Except if it’s Dr Cooper’s patient, and then you will
rest assured that the patient will get a mediastinoscopy.
Dr Walter Weder (Zurich, Switzerland). Why do you exclude
all patients with N2 disease since dyspnea is reduced and quality
of life improved after this procedure and long-term survival is of
minor importance?
Dr Choong. The reason we exclude N2 disease is because we
believe that patients with N2 disease have a much poorer progno-
sis, with a 5-year survival of around 10%. I think this surgery is not
something to be taken lightly. I think they were being treated by a
very experienced group of surgeons, but patients with N2 disease
have poor long-term survival prognosis, and therefore were not
offered the treatment.
Dr Darroch W. O. Moores (Albany, NY). I have a technical
question. When you do these lobectomies in these patients, do you
dissect the fissure or do you staple the fissure mass? Dissecting
these fissures, I think, would be a big problem and you would have
a lot of air leaks. Is there a different technique for a lobectomy in
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cancer without lung volume reduction?
Dr Choong. If you don’t mind, I will refer this to the experts.
Dr Cooper. Although some lower lobectomies were done, the
most common lobectomy in this situation would be an upper
lobectomy, a right upper lobectomy, and although I would prefer
normally not to staple a fissure to preserve the volume of the
remaining lung, in these cases it would be stapled with a buttressed
staple line, but it’s usually the last thing done. It otherwise is a
complete anatomic lobectomy, like you would do for anything
else, with the individual ligation of the vessels and closure of the
bronchus, and then finally, at the end, stapling off the fissure with
a buttressed staple line.
Dr Peter W. Barrett (New Haven, Conn). Dr Kaiser is a
proponent of little or no pleural suction. Are you guys in favor of
that, and, if so, how many days do you wait?
Dr Cooper. As most of you know, I was maniacal about usingThe Journal of Thoracichad to get the lung up against the chest wall to stop air leaks. Then
I realized that all you’re doing is tearing the lung more and that,
unlike you or I, a 20% pneumothorax or a little positive pleural
pressure does not lead to lung collapse. The patients have obstruc-
tive lung disease with loss of elastic recoil and their lungs don’t
collapse so easily. So that’s when we began using only straight
drainage, and this resulted in a shortened hospital stay. So our
general rule is that they go to water-seal. If there’s more than a
50% pneumothorax or if there is compression of remaining lung or
if the degree of subcutaneous emphysema is unbearable, then we
will put on a little bit of suction. Otherwise we’ll leave it on
water-seal for a couple of days. If there’s a quarter of the chest
filled with air, well, it was filled with emphysematous lung before
and now it’s filled with air—no problem. Then at about 48 hours,
if we still have a space and it has become a problem, we might
begin to cautiously increase the suction, feeling we’re not going to
tear the lung quite as much at that stage, by increasing the transpul-suction in the early days of volume reduction, thinking that you monary pressure.and Cardiovascular Surgery ● Volume 127, Number 5 1331
